目的 探讨正清风痛宁缓释片联合普瑞巴林治疗带状疱疹后遗神经痛的临床效果。方法 选取2019年1月—2020年12月河南科技大学第一附属医院收治的130例带状疱疹后遗神经痛患者，按随机数字表法分成对照组和治疗组，每组各65例。对照组口服普瑞巴林胶囊，起始剂量75 mg/次，2次/d，连用1周后增至150 mg/次，2次/d。治疗组在对照组基础上口服正清风痛宁缓释片，2片/次，2次/d。连续治疗4周后评价两组疗效。比较治疗前后两组疼痛视觉模拟量表（VAS）评分、失眠严重程度指数（ISI）总分、36项健康调查简表（SF-36）总分及血清白细胞介素（IL）-17、C反应蛋白（CRP）、前列腺素E₂（PGE₂）水平。结果 治疗后，治疗组总有效率为95.4%，显著高于对照组的84.6%（P＜0.05）。治疗后，治疗组止痛起效时间和疼痛缓解时间均较对照组显著缩短（P＜0.05）。治疗后，两组疼痛VAS评分、ISI总分均显著低于治疗前，SF-36总分均显著高于治疗前（P＜0.05）；且治疗后，治疗组疼痛VAS评分、ISI总分和SF-36总分改善均显著优于对照组（P＜0.05）。治疗后，两组血清IL-17、CRP和PGE₂水平均显著下降（P＜0.05）；且治疗后，治疗组血清IL-17、CRP和PGE₂水平均显著低于对照组（P＜0.05）。结论 正清风痛宁缓释片联合普瑞巴林对带状疱疹后遗神经痛患者具有确切的临床疗效，能安全有效地缓解患者疼痛、改善睡眠与生活质量，并可进一步抑制血清IL-17、CRP和PGE₂水平。

Objective To investigate the clinical effect of Zhengqing Fengtongning Sustained-release Tablet combined with pregabalin in treatment of postherpetic neuralgia.Methods A total of 130 patients with postherpetic neuralgia who were admitted to The First Affiliated Hospital of Henan University of Science and Technology from January 2019 to December 2020 were selected and divided into control group (n =65) and treatment group (n=65) according to the random number table method.Patients in the control group were po administered with Pregabalin Capsule,the initial dose was 75 mg/time,twice daily,and then increased to 150 mg/time,twice daily after continuous use for 1 week.Patients in the treatment group were po administered with Zhengqing Fengtongning Sustained-release Tablet on the basis of the control group,2 tablet/time,twice daily.The analgesic efficacy of the two groups was evaluated after 4 weeks of continuous treatment.The pain visual analog scale (VAS) score,insomnia severity index (ISI) total score,36-item short form of health survey (SF-36) total score,serum interleukin (IL)-17,C-reactive protein (CRP),prostaglandin E₂(PGE₂) levels were compared between the two groups before and after treatment.Results After treatment,the total effective rate of the treatment group was 95.4%,which was significantly higher than 84.6% of the control group (P<0.05).After treatment,the analgesic onset time and pain relief time in the treatment group were significantly shorter than those in the control group (P<0.05).After treatment,the VAS score and ISI total score of pain in the two groups were significantly lower than before treatment,but the SF-36 total score was significantly higher than before treatment (P<0.05).After treatment,the VAS score,ISI total score,and SF-36 total score of the treatment group were significantly improved than those of the control group (P<0.05).After treatment,the serum levels of IL-17,CRP,and PGE₂ in the two groups were significantly decreased (P<0.05).After treatment,the levels of serum IL-17,CRP,and PGE₂ in the treatment group were significantly lower than those in the control group (P<0.05).Conclusion Zhengqing Fengtongning Sustained-release Tablet combined with pregabalin has definite clinical effect in treatment of postherpetic neuralgia,and can safely and effectively relieve pain,improve sleep and life quality,which can inhibit the levels of serum IL-17,CRP,and PGE₂.

R971

河南科技大学青年科学基金资助项目(2020QN035)